Coagulation Profile (PT/INR, aPTT, Fibrinogen, and D-Dimer)

The standard clinical coagulation profile — comprising the Prothrombin Time / International Normalized Ratio (PT/INR), Activated Partial Thromboplastin Time (aPTT), Fibrinogen, and D-Dimer — is the definitive laboratory panel evaluating secondary hemostasis, the enzymatic coagulation cascade, fibrin clot polymerization, and downstream fibrinolysis.

Historically, the enzymatic coagulation cascade was divided into two distinct in vitro pathways converging onto a common pathway:

1. The Extrinsic Pathway (PT/INR): Initiated when vascular disruption exposes subendothelial Tissue Factor (TF) to circulating plasma Factor VII. The TF:VIIa complex activates Factor X to Xa, requiring calcium and tissue phospholipids.
2. The Intrinsic Pathway (aPTT): Initiated through contact activation of Factor XII (Hageman factor) with negatively charged surfaces, activating sequentially Factor XI, Factor IX, and together with cofactor Factor VIIIa, forming the "tenase" complex on activated platelet membranes to activate Factor X.
3. The Common Pathway: Factor Xa, supported by cofactor Va, forms the prothrombinase complex on platelet membranes, cleaving prothrombin (Factor II) into thrombin (Factor IIa). Thrombin subsequently cleaves soluble fibrinogen (Factor I) into insoluble fibrin monomers, which polymerize and are covalently cross-linked by activated Factor XIIIa into a secure, stable hemostatic mesh.

In the modern cell-based model of in vivo hemostasis, coagulation occurs on cell surfaces through three overlapping phases: Initiation (on tissue-factor-bearing cells generating trace thrombin), Amplification (where trace thrombin primes platelets and activates factors V, VIII, and XI), and Propagation (large-scale burst of thrombin on activated platelet phosphatidylserine surfaces).

Once vascular repair is underway, endothelial cells release Tissue Plasminogen Activator (tPA), converting plasminogen into active plasmin. Plasmin cleaves insoluble, Factor XIIIa-crosslinked fibrin clots, liberating specific neo-antigenic degradation fragments designated D-Dimers (two crosslinked D-domains of adjacent fibrin monomers). Elevated circulating D-dimer confirms that thrombin generation and plasmin-mediated fibrin degradation have simultaneously occurred in vivo.

Coagulation assays are among the most sensitive tests to pre-analytic errors in clinical pathology:

• The Critical 9:1 Blood-to-Citrate Ratio: Blood must be drawn into a light blue-top tube containing 3.2% (0.109 M) buffered sodium citrate. The ratio of whole blood to anticoagulant must be strictly 9:1. If the tube is underfilled (< 90% capacity), excess free liquid citrate chelates the diagnostic calcium chloride reagent added during analysis, falsely prolonging both PT and aPTT!
• Order of Draw: Citrate tubes must be drawn second (after non-additive blood culture tubes, but before serum separator, heparin, or EDTA tubes). Never draw coagulation tubes immediately after EDTA (lavender top) or heparin (green top) tubes, as minute needle-tip contamination causes severe false prolongation.
• Polycythemia Adjustment: In patients with severe erythrocytosis (hematocrit > 55%), the relative plasma volume in the tube is reduced. The fixed volume of citrate anticoagulant will over-citrate the small plasma volume. The laboratory must prepare an adjusted tube with reduced citrate volume using the standard formula:

$Citrate Volume = (100 - Hematocrit) × frac{Total Blood Volume}{595 - Hematocrit}$

• Processing Time: Samples must be centrifuged at 1,500–2,000× g for 15 minutes to produce platelet-poor plasma (PPP, platelets $< 10 \times 10^9/\text{L}$). Platelets contain Factor IV (platelet factor 4), which neutralizes heparin in vitro. Testing must occur within 4 hours of venipuncture for aPTT and within 24 hours for PT.

1. Investigation of Bleeding Diatheses: Spontaneous mucocutaneous bleeding, recurrent epistaxis, heavy menstrual bleeding, hemarthroses, hematomas, or delayed post-procedural hemorrhage.
2. Pre-Operative Hemostatic Clearance: Pre-surgical screening in patients with personal/family bleeding histories, liver disease, malnutrition, or major neurosurgical/cardiac interventions.
3. Monitoring Anticoagulant Pharmacotherapy:

• Warfarin (Vitamin K Antagonist): Monitored via PT/INR.
• Unfractionated Heparin (UFH): Monitored via therapeutic aPTT (target 1.5–2.5× baseline control) or anti-Factor Xa assay.

1. Diagnosis of Disseminated Intravascular Coagulation (DIC): Sepsis, massive trauma, amniotic fluid embolism, placental abruption, or acute promyelocytic leukemia.
2. Exclusion of Venous Thromboembolism (DVT and PE): D-Dimer screening in low- or intermediate-probability patients.
3. Evaluation of Liver Synthetic Function: Monitoring acute liver failure and end-stage cirrhosis (Factor VII has a 4-hour half-life; INR is the most rapid marker of hepatic necrosis).

┌─────────────────────────────────────────────────────────────┐
│          STEP-BY-STEP COAGULATION PROFILE PROTOCOL          │
├─────────────────────────────────────────────────────────────┤
│ Step 1: Examine PT/INR and aPTT Concurrently                │
│         ├─ Pattern 1: Isolated Prolonged PT/INR             │
│         │  (aPTT is normal) → Go to Step 2                  │
│         ├─ Pattern 2: Isolated Prolonged aPTT               │
│         │  (PT/INR is normal) → Go to Step 3                │
│         ├─ Pattern 3: Both PT/INR and aPTT Prolonged        │
│         │  → Go to Step 4                                   │
│         └─ Pattern 4: Both Normal with Bleeding:            │
│            Platelet dysfunction, vWD, or Factor XIII defect │
├─────────────────────────────────────────────────────────────┤
│ Step 2: Isolated Prolonged PT/INR Workup                    │
│         Factor VII has the shortest half-life (~4 hours).   │
│         Causes: Early Vitamin K deficiency, early liver     │
│         disease, Warfarin initiation, congenital Factor VII │
│         deficiency.                                         │
├─────────────────────────────────────────────────────────────┤
│ Step 3: Isolated Prolonged aPTT Workup                      │
│         Perform 50:50 Mixing Study (Patient + Normal Plasma)│
│         ├─ aPTT Corrects: Factor Deficiency                 │
│         │  (Hemophilia A [VIII], Hemophilia B [IX], XI, XII)│
│         └─ aPTT Fails to Correct: Circulating Inhibitor     │
│            1. Lupus Anticoagulant (Antiphospholipid syndr)  │
│            2. Acquired Factor VIII inhibitor (severe bleed) │
│            3. Unfractionated heparin contamination          │
├─────────────────────────────────────────────────────────────┤
│ Step 4: Combined Prolonged PT/INR and aPTT Workup           │
│         Common pathway defect (X, V, II, Fibrinogen), OR    │
│         multi-factor depletion:                             │
│         ├─ Check Fibrinogen, Platelets, and D-Dimer:        │
│         │  ├─ Low Fibrinogen + Low Platelets + High D-Dimer:│
│         │  │  ACUTE CONSUMPTIVE DIC                         │
│         │  ├─ Normal/High Fibrinogen + Normal Platelets:    │
│         │  │  Severe Vitamin K deficiency, severe cirrhosis,│
│         │  │  supratherapeutic DOAC or Warfarin + Heparin   │
│         │  └─ Isolated Low Fibrinogen: Dysfibrinogenemia    │
├─────────────────────────────────────────────────────────────┤
│ Step 5: D-Dimer Rule-Out Algorithm (for VTE)                │
│         Assess clinical Wells score first:                  │
│         ├─ If Low/Unlikely risk: D-Dimer < Age x 10 ug/L    │
│         │  rules out DVT/PE without imaging.                │
│         └─ If High/Likely risk: SKIP D-Dimer; proceed       │
│            directly to CTPA or compression ultrasound!      │
└─────────────────────────────────────────────────────────────┘

• Unfractionated Heparin Contamination: Blood drawn from central venous catheters, arterial lines, or PICC lines frequently contains residual heparin flush. Heparin binds antithrombin and massively prolongs aPTT. Perform a Thrombin Time (TT) or Reptilase Time: heparin prolongs TT but leaves Reptilase Time unaffected (Reptilase is immune to heparin-antithrombin inhibition).
• Direct Oral Anticoagulants (DOACs):
• Direct Factor Xa Inhibitors (Rivaroxaban, Apixaban, Edoxaban): Variable and unpredictable effects on PT and aPTT. Normal PT/aPTT does NOT exclude therapeutic drug levels. Quantify using anti-Factor Xa assays calibrated specifically for the drug.
• Direct Thrombin Inhibitors (Dabigatran): Markedly prolongs Thrombin Time (TT); quantify using Dilute Thrombin Time (dTT) / Ecarin clotting time.
• Lupus Anticoagulant Assay Artifact: Antiphospholipid antibodies bind to the phospholipid reagents used in the aPTT assay, prolonging clotting time in vitro. In vivo, these patients are hypercoagulable (thrombosis risk), NOT prone to bleeding!

1. The "Pre-Op Coagulation Screen" Fallacy: Routine testing of PT/INR and aPTT in unselected, healthy patients with no bleeding history has near-zero predictive value for surgical bleeding and high false-positive rates that cause unnecessary surgical cancellations. A detailed, structured bleeding history is far superior.
2. Missing Factor XIII Deficiency: Factor XIII covalently cross-links soluble fibrin monomers into insoluble fibrin polymers. Congenital or acquired Factor XIII deficiency presents with severe, life-threatening delayed bleeding (e.g. umbilical stump bleeding, intracranial hemorrhage), yet PT/INR, aPTT, fibrinogen, and platelet counts are 100% completely normal! Requires a specific Factor XIII clot solubility assay.
3. Using D-Dimer in High-Probability Patients: Ordering D-dimer in a patient with a high clinical pre-test probability of pulmonary embolism (e.g. Wells score > 6) is a critical error. A negative D-dimer in a high-probability patient does NOT rule out PE (false-negative rate up to 15% to 20%); high-risk patients must proceed directly to CTPA.

• The Factor VII Clue: Factor VII has the shortest half-life of all coagulation factors (~4 to 6 hours). Therefore, when hepatic synthesis halts (acute liver failure, paracetamol overdose) or Vitamin K is blocked (warfarin initiation), Prothrombin Time (PT/INR) is the FIRST test to become abnormal, while aPTT remains normal.
• The 50:50 Mixing Rule:
• Mix corrects = Deficiency (replete the missing factor).
• Mix does not correct = Inhibitor (Lupus anticoagulant or acquired Factor VIII inhibitor).
• The D-Dimer Negative Predictive Power: D-dimer has poor specificity (elevated in pregnancy, age > 65, inflammation, cancer, post-op, trauma), but its Negative Predictive Value is $> 99.5\%$. Use it ONLY to rule out VTE in low/intermediate probability patients, never to rule it in.
• Reptilase vs Thrombin Time: If aPTT is mysteriously prolonged in a hospital patient, order Thrombin Time and Reptilase Time. If TT is prolonged but Reptilase is normal → The sample was drawn from a line contaminated with Heparin.

• Complete Blood Count (CBC): Essential enumeration of platelet count and hematocrit (Complete Blood Count).
• Peripheral Blood Film (PBF): Evaluates for schistocytes in microangiopathic hemolytic anemia and DIC (Peripheral Blood Film).
• Liver Function Tests (LFT): Assesses underlying hepatocellular parenchymal disease and cirrhosis (Liver Function Tests).
• Wells Criteria for DVT & PE Calculator: Clinical decision tool determining pre-test probability before ordering D-dimer (Wells Criteria).
• Specific Coagulation Factor Assays: Quantitative measurement of individual factor activities (VII, VIII, IX, XI, von Willebrand antigen).